Internal Review Boards
RSSArticles
-
Transparency About Participation Incentives Could Benefit IRBs, Researchers, and Patients
While the issue of incentives raises a host of ethical issues for discussion, the problem is the dearth of data on what study participants have been compensated for all manner of studies and clinical trials.
-
What You Don’t Know About NIH RAC Review Changes Could Hurt
IRBs might not have asked for it, but the National Institutes of Health and the FDA have handed them a new responsibility when it comes to oversight of clinical trials involving human gene transfer.
-
Who was Dan Markingson?
On May 8, 2004, Dan Markingson killed himself while participating in a University of Minnesota Department of Psychiatry drug study.
-
U. of Minnesota Fights Bill Giving State Oversight of Psych Research
Reeling from a decade-long series of investigations and allegations after the suicide of a psychiatric research patient, the University of Minnesota is now facing a proposed state law that would assign oversight for its psychiatric drug research program to an independent ombudsman’s office.
-
AMA calls for clinical trial transparency
The American Medical Association has joined the AllTrials initiative, giving the campaign for clinical trial data transparency a formidable ally with the largest physician membership in the U.S.
-
Here’s how to improve reviews of socio-behavioral protocols
IRBs that predominantly review biomedical protocols might find it less clear in determining risks when reviewing socio-behavioral research.
-
Ethics tool could enhance protocols and subject protection
A multiple stakeholder group developed a protocol ethics tool kit to ensure there is no missing information regarding ethics considerations in protocols.
-
Next stage for IRB collaborations: Better communication and connections
It’s complicated for research organizations to operationalize oversight of studies when relying on a single IRB for review of a multisite study, and the Notice of Proposed Rulemaking might even complicate things more.
-
‘Optimistic bias’ may subvert informed consent in early-phase cancer trials
There is a gray area where optimism in a research patient in early phase cancer trials crosses over to a misperception of benefit and raises ethical questions about informed consent.
-
Maryland Gets a New View of Conflicts of Interest
An investigative committee at the University of Maryland in College Park recommends mandatory education on conflicts of interest for research faculty.